Through collaborative hit-to-lead projects, identify new leads with activity in animal models of disease and the potential for further optimization
current phase of drug development
updated 1 Mar 2022
Hit-to-lead is a dynamic phase in the drug discovery process in which small molecule hits from high throughput screens or other lead identification efforts are evaluated and undergo optimization to identify promising lead compounds.
The process of hit-to-lead optimization is ongoing, with multiple series being progressed based on outputs of the screening programme. A variety of hit-to-lead mechanisms and exploration strategies are being used to progress towards in vivo proof-of-concept studies in pre-clinical efficacy models of leishmaniasis.
The NTD Drug Discovery Booster is a related project conducting early-stage drug discovery to identify new treatments for leishmaniasis and Chagas disease.
Get our latest news, personal stories, research articles, and job opportunities.